The MINA-CM project, Madrid Innovative Neurotech Alliance, P2022-BMD-7236, backed by the Community of Madrid within the framework of the 2022 Biomedicine R&D grants, will be carried out during the period 2023-2025.

MINA-CM brings together a wide consortium of prominent researchers from the Community of Madrid, complemented and integrated with patient associations, technology companies, and foundations, thus providing a social, economic, and business dimension.

Madrid Innovative Neurotech Alliance (MINA-CM) aims to innovate, develop, and implement state-of-the-art neurotechnological solutions in the Community of Madrid. MINA-CM’s transformative vision seeks to revolutionize the treatment of brain injuries, strokes, and other neurological conditions, such as neurodegenerative diseases, through advances in neuroprotection, targeted neuroplasticity, and the development of neural devices to restore or enhance sensory and motor function, brain stimulation, as well as cognitive rehabilitation and enhancement.

MINA-CM is structured around 5 neurotechnological areas representing the challenges facing our society:

  • Brain neuromodulation and stimulation: Includes invasive and non-invasive stimulation, as well as stimulation to prevent/delay cognitive frailty and disability, and the effect of exercise.
  • Brain imaging: Focuses on new combined techniques and algorithms based on structural and functional aspects to improve diagnostic and therapeutic capabilities.
  • Advanced neuroprosthetics: Encompasses neural interfaces, cellular/molecular systems, and robotics to replace sensory, motor, or cognitive functions, as well as brain-computer interfaces.
  • Big Data and machine learning: Dedicated to the recording, collection, and analysis of brain data.
  • Advanced molecular and cellular neurotherapy: Focused on new targets and neuroprotective and neuroregenerative treatments.


13 research groups:

The Biomaterials and Regenerative Engineering Group (GBIR), The Ageing Lab-UPM, The B105 Electronic Systems Lab-UPM, ImFINE, from the Faculty of Physical Activity and Sports Sciences-INEF-UPM, The Neurocomputing and Neurorobotics Group (GNN-UCM), The Research, Innovation, Surgery, and Neuroengineering Group (ICyN)-HCSC, The Experimental Neurology Unit-UPM, The Neuroproteins-Stroke Research Group, NEUROL-HRyC, The Medical Chemistry Laboratory-CSIC, The Clinical Neuroscience Laboratory (LNC)-UPM, the NEUROSUR-HCSC research group, The Optic Nerve Repair Research Team (RNO-HPAZ), and the IPTC-UPM

and 9 associated groups:

MINA-CM Associated Groups contribute to the social and economic translation dimension.

Parkinson Madrid Association, Macula-Retina Association, Spanish Stroke Federation, Cognitive Deterioration Prevention Center of the Madrid City Council, Marcelino Botín Foundation, the European eBRAINS network, and the companies Ischaemia Biotech, Bioactive Surfaces, and Silk Biomed.

Bookmark the permalink.

Comments are closed.